<?xml version="1.0" encoding="UTF-8"?>
<p id="p0005">In December 2019 a new type of pneumonia supported by a novel member of the coronoviridae family named SARS-CoV-2 (severe acute respiratory coronavirus 2 syndrome) developed from Wuhan Province in China [
 <xref rid="bb0005" ref-type="bibr">1</xref>]. Phylogenetic analysis demonstrated that this is a different virus with ~80% nucleotide identity with SARS-CoV-1 [
 <xref rid="bb0010" ref-type="bibr">2</xref>]. The disease caused by SARS-CoV-2 is characterized by dry cough, fever, dyspnea and fatigue, accompanied by lymphopenia [
 <xref rid="bb0015" ref-type="bibr">[3]</xref>, 
 <xref rid="bb0020" ref-type="bibr">[4]</xref>, 
 <xref rid="bb0025" ref-type="bibr">[5]</xref>, 
 <xref rid="bb0030" ref-type="bibr">[6]</xref>]. In more severe cases (apparently up to 15â€“20% of infected patients) the picture may become more complicated by the onset of interstitial pneumonia with alveolar damage, which clinically can lead to severe Acute Respiratory Distress Syndrome (ARDS) and even death [
 <xref rid="bb0035" ref-type="bibr">7</xref>]. Since the initial outbreak, the epidemic has had a rapid global spread worldwide which led the World Health Organization (WHO) to declare the disease now called COVID-19 a Public Health Emergency of International Concern on 30th January 2020 and a pandemic on 11th March 2020. The epidemiological picture is constantly evolving, and data updated as of March 17th count 159 countries involved with more than 185,000 cases and 7500 confirmed deaths [
 <xref rid="bb0040" ref-type="bibr">8</xref>].
</p>
